Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: that (1) co-administration of rosiglitazone with recombinant human growth hormone (rhGH) will abrogate the adverse effect of rhGH on insulin sensitivity that may be mediated by increased free fatty acid (FFA) turnover and will have a synergistic effect on reducing visceral adiposity; and (2) the effects of rosiglitazone and rhGH on subcutaneous adipose tissue volume will be determined by their effects on total energy balance. Primary Objectives: to determine (1) the individual and interacting effects of rosiglitazone and rhGH on insulin sensitivity, as assessed by frequently sampled intravenous glucose tolerance test, in HIV-infected subjects with visceral adiposity and insulin resistance; and (2) the individual and interacting effects of rosiglitazone and rhGH on body composition assessed by whole body MRI and dual energy X-ray absorptiometry (DEXA) in HIV-infected subjects with visceral adiposity and insulin resistance.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000047-46
Application #
7378403
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
46
Fiscal Year
2006
Total Cost
$262,552
Indirect Cost

  Institution

Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

de Simone, Giovanni; Wang, Wenyu; Best, Lyle G et al. (2017) Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol 16:64
Gerber, Linda M; Sievert, Lynnette L; Schwartz, Joseph E (2017) Hot flashes and midlife symptoms in relation to levels of salivary cortisol. Maturitas 96:26-32
De Marco, Marina; Gerdts, Eva; Mancusi, Costantino et al. (2017) Influence of Left Ventricular Stroke Volume on Incident Heart Failure in a Population With Preserved Ejection Fraction (from the Strong Heart Study). Am J Cardiol 119:1047-1052
Schachterle, William; Badwe, Chaitanya R; Palikuqi, Brisa et al. (2017) Sox17 drives functional engraftment of endothelium converted from non-vascular cells. Nat Commun 8:13963
Haring, Bernhard; Wang, Wenyu; Fretts, Amanda et al. (2017) Red meat consumption and cardiovascular target organ damage (from the Strong Heart Study). J Hypertens 35:1794-1800
Beheshtian, Azadeh; Shitole, Sanyog G; Segal, Alan Z et al. (2016) Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults. Atherosclerosis 253:47-53
Leung, Vivien; Chiu, Ya-Lin; Kotler, Donald P et al. (2016) Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation. HIV Clin Trials 17:55-62
de Simone, Giovanni; Roman, Mary J; De Marco, Marina et al. (2015) Hemodynamic Correlates of Abnormal Aortic Root Dimension in an Adult Population: The Strong Heart Study. J Am Heart Assoc 4:e002309
Bhatia, Rajeev; Lesser, Daniel J; Oliveira, Flavia G S A et al. (2015) Body Fat Composition: A Predictive Factor for Sleep Related Breathing Disorder in Obese Children. J Clin Sleep Med 11:1039-45
Ocean, Allyson J; Christos, Paul; Sparano, Joseph A et al. (2014) Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs 32:542-8

Showing the most recent 10 out of 370 publications